Victory Capital Management
ABUS icon

Victory Capital Management’s Arbutus Biopharma ABUS Stock Holding History

Victory Capital Management’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-13,810
Closed -$28K – 2537
2023
Q3 		$28K Buy
13,810
+815
+6% +$1.71K ﹤0.01% 2428
2023
Q2 		$29.9K Sell
12,995
-302
-2% -$786 ﹤0.01% 2426
2023
Q1 		$40.3K Buy
+13,297
New +$37.5K ﹤0.01% 2461
2018
Q4 		– Sell
-151,060
Closed -$1.43M – 1778
2018
Q3 		$1.43M Sell
151,060
-7,660
-5% -$76.1K ﹤0.01% 1184
2018
Q2 		$1.16M Sell
158,720
-8,430
-5% -$50.2K ﹤0.01% 1218
2018
Q1 		$836K Buy
167,150
+16,430
+11% +$87K ﹤0.01% 1274
2017
Q4 		$761K Buy
150,720
+21,460
+17% +$126K ﹤0.01% 1273
2017
Q3 		$801K Sell
129,260
-3,550
-3% -$15.2K ﹤0.01% 1259
2017
Q2 		$478K Buy
+132,810
New +$457K ﹤0.01% 1319

Other funds holding ABUS

WCM
Whitefort Capital Management New York $406M AUM 84.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Victory Capital Management's ABUS Position: Q4 2023 in Review

Victory Capital Management sold out of Arbutus Biopharma (ABUS) in Q4 2023, closing a stake of 13,810 shares — an estimated $28K sold.

Victory Capital Management first reported a position in ABUS in Q2 2017 and held it in 9 quarters. The position peaked at $1.43M in Q3 2018. 112 funds tracked by Wall St. Rank hold ABUS as of Q4 2023.

  • Victory Capital Management reported no remaining Arbutus Biopharma position as of Q4 2023 after selling out during the quarter.
  • Victory Capital Management sold 13,810 Arbutus Biopharma shares in Q4 2023, an estimated $28K.
  • Victory Capital Management first reported a position in Arbutus Biopharma in Q2 2017 and held it in 9 quarters.
  • Victory Capital Management's Arbutus Biopharma position peaked at $1.43M in Q3 2018.
  • 112 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q4 2023.

Based on Victory Capital Management's 13F filing for Q4 2023, filed 5 Feb 2024.